Archive · 7 Jun 2025
Dr. Reddy's Laboratories Faces New Challenges
Dr. Reddy's Laboratories is a company that makes medicine.
They made a lot of money selling a generic version of a drug called Revlimid in the US for the past three years.
Now, that money is starting to slow down.
They are investing in new opportunities, like drugs for diabetes, which should bring more money in the future.
They are also buying other companies and working with partners to sell more products, and investing in research and development for future drugs.
While the company has made good money recently, future earnings depend on their new ventures.
Dr. Reddy's benefitted from gRevlimid sales, which is ending by FY26.
The company is investing in GLP-1RA generics (diabetes drugs), with expected launches from January 2026.
Dr. Reddy's acquired Nicotine Replacement Therapy products from Haleon in September 2024.
The company is leveraging partnerships with Nestle and Sanofi to expand product reach.
Dr. Reddy’s is expanding its R&D portfolio with biosimilars and early-stage oncology assets.
- Who
- Dr. Reddy's Laboratories.
- What
- An analysis of Dr. Reddy's Laboratories' financial performance, future prospects, and strategic investments.
- When
- The article was published on June 7, 2025.
- Where
- Primarily the US, Canada, India, Brazil, and Europe.
- Why
- To assess the company's current financial position, evaluate its strategic moves, and predict future performance.
- FY22-25 Revenue Growth
- 15% CAGR
- FY22-25 PAT Growth
- 36% CAGR
- EBITDA Margin Expansion
- 400 bps
- Net Cash (March 2025)
- ₹2,454 crore
- R&D Investment
- 8.5% of sales